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Aim To compare the blood lactate levels between patients 
with psychotic disorder receiving first- and those receiving 
second-generation antipsychotics.
Methods The study was conducted at the psychiatric in-
patient and outpatient clinics of the Split Clinical Hospital 
from June 6, 2008 to October 10, 2009. Sixty patients with 
psychotic disorder who were assigned to 6-month treat-
ment were divided in two groups: 30 received haloperidol 
(first generation antipsychotic) and 30 received olanzap-
ine (second generation antipsychotic). Blood lactate levels, 
other metabolic parameters, and scores on the extrapyra-
midal symptom rating scale were assessed.
Results  Patients  receiving  haloperidol  had  significantly 
higher blood lactate levels than patients receiving olan-
zapine (P < 0.001). They also more frequently had parkin-
sonism, which was significantly correlated with both halo-
peridol treatment at 1 month (P < 0.001) and 6 months 
(P = 0.016) and olanzapine treatment at baseline (P = 0.016), 
3 months (P = 0.019), and 6 months (P = 0.021). Also, pa-
tients receiving haloperidol had significant correlation be-
tween blood lactate and dystonia at 1 month (P < 0.001) 
and 6 months (P = 0.012) and tardive dyskinesia at 1 month 
(P = 0.032). There was a significant difference between the 
treatment groups in lactate levels at all points from base-
line to month 6 (P < 0.001).
Conclusion It is important to be aware of the potential ef-
fect of haloperidol treatment on increase in blood lactate 
levels and occurrence of extrapyramidal side effects. There-
fore, alternative antipsychotics should be prescribed with 
lower risk of adverse side effects.
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Due to their heterogeneity, antipsychotics are difficult 
to classify, but they are frequently categorized as the 
first- and second-generation based on the incidence of 
extrapyramidal side effects, ie, antidopaminergic activ-
ity (1,2). First-generation antipsychotics have dominant 
antidopaminergic activity and pronounced extrapyra-
midal side effects (1), while second-generation antipsy-
chotics have a pronounced effect on other neurotrans-
mitter systems, as well as sporadic extrapyramidal side 
effects.
Antipsychotics  block  numerous  neurotransmitter  recep-
tors in a manner that induces therapeutic effects and side 
effects, which may vary in intensity and produce serious 
consequences (3-7). Extrapyramidal side effects (adverse 
cardiovascular,  hematological,  gastrointestinal,  sexual, 
and urologic effects) are most frequently manifested in 
first-generation antipsychotics due to their non-selective 
dopaminergic block (1,8-10). The consequence of a dop-
aminergic effect on the tuberoinfundibular system causing 
dopamine to inhibit prolactin secretion is hyperprolactine-
mia (11,12), with possible consequences such as tissue hy-
poxia and mortality (13-15).
Particular attention today is paid to the effects of first-
generation antipsychotics on metabolic disorders. Nu-
merous  studies  have  shown  that  first-generation  an-
tipsychotic  therapy  may  lead  to  metabolic  changes, 
particularly changes in the regulation of glucose, lipid 
levels, and body weight (3-5,13-21). These side effects 
are associated with increased mortality and substantial 
morbidity including diabetes, hypertension, and cardio-
vascular disease (22,23). In many years of clinical prac-
tice, we have empirically observed that treatment with 
certain antipsychotics causes, along with recognized and 
described metabolic disorders, an increase in the blood 
lactate levels. Increased lactate levels are generally asso-
ciated with increased morbidity and mortality in patients 
with chronic illnesses or critically ill patients (13,14,24-
26). A review of the literature did not find any studies 
on the effect of antipsychotic therapy on lactate levels 
or such changes as a part of other antipsychotic side ef-
fects. Therefore, it is important to investigate this phe-
nomenon in patients taking first- or second-generation 
antipsychotic medication.
We hypothesized that a 6-month treatment with haloperi-
dol or olanzapine would change blood lactate levels and 




Men aged 20-50 years with psychotic relapse or newly 
diagnosed psychotic disorder who were not taking any 
medications apart from the prescribed antipsychotic in the 
period of one month before the study were recruited from 
psychiatric  inpatient  and  outpatient  clinics  of  the  Split 
Clinical Hospital. Exclusion criteria were female sex, base-
line lactate levels over 2.0 mmol/L, tobacco use, and previ-
ously diagnosed diabetes mellitus. Women were excluded 
due to significant oscillations in plasma lactate levels dur-
ing menstruation (27-30). Psychiatric diagnoses and past 
treatment history were evaluated by chart review, inter-
view with treatment clinicians, and clinical interview with 
the patient and/or caregiver in accordance with the Inter-
national Classification of Diseases ICD-10 criteria. Each par-
ticipant had previously been informed of the outline of the 
study and gave a signed the informed consent. This study 
was approved by the Ethics Committee of the University of 
Split School of Medicine.
Study design
A  non-randomized,  prospective,  assessor-blind  design 
was used. One group of 30 participants was given halo-
peridol  (first-generation  antipsychotic)  and  another 
group of 30 participants was given olanzapine (second-
generation  antipsychotic).  Similar  studies  (31,32)  have 
used fewer than 40 participants, but we applied a more 
conservative  approach  and  used  60  participants.  The 
study lasted from June 6, 2008 to October 10, 2009. The 
dose of all medications remained unchanged during the 
study period.
Assessments
Baseline assessments included demographics and meta-
bolic  parameters.  The  extrapyramidal  symptom  rating 
scale (ESRS) was used to investigate four types of antipsy-
chotic-induced movement disorders: parkinsonism, akath-
isia, dystonia, and tardive dyskinesia (33). The independent 
examiner who evaluated extrapyramidal side effects was 
blind to the patients’ therapy assignment.
Laboratory assessment at baseline included lactate, fasting 
glucose, blood pressure, and weight. Follow-up visits oc-
curred at 1, 3, and 6 months after the study initiation. At 
each follow-up visit, all baseline evaluations were repeat-43 Glavina et al: Antipsychotics and blood lactate levels
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ed. Capillary blood was collected from the finger pad by 
a sterile lancet and capillary tube and analyzed at the Split 
Clinical Hospital Central Laboratory.
The primary outcome included the changes in lactate lev-
els. In a healthy adult, the reference values of blood lactate 
level are <1.5 mmol/L to 10-15 mmol/L during exertion. In 
patients suffering from critical illness, moderate increase in 
blood lactate levels can range from 2-4.0 mmol/L, where-
as levels >4.0 mmol/L are critically high. Lactate levels in 
patients suffering from metabolic diseases can range from 
5-15  mmol/L  (34). The  major  secondary  outcome  were 
changes in ESRS scores.
Statistical analysis
All analyses were performed using the SPSS, version 13.0 
(SPSS  Inc.,  Chicago,  IL,  USA).  Continuous  variables  were 
presented using summary statistics such as means and 
standard deviations. Categorical variables were presented 
using frequencies and percentages. Baseline characteris-
tics were compared using independent samples t test. An-
tipsychotic treatment type and blood lactate levels from 
baseline to endpoint were compared by two-way repeat-
ed measures ANOVA to test the significance of mean dif-
ferences, followed by a series of post-hoc pairwise t tests 
and Bonferroni correction to test the probability at which 
to accept any of these tests. Therefore, we accepted pair-
wise t tests as being significant only if they were P < 0.0167. 
Greenhouse-Geisser corrections were made when the as-
sumption of sphericity was violated (35). The relationship 
between blood lactate level and ESRS changes was exam-
ined using Spearman correlation. Differences were consid-
ered significant at P < 0.05.
ReSUlTS
Demographic and basic descriptive data
The two treatment groups did not differ significantly in 
age or baseline glucose, weight, and systolic and diastol-
ic blood pressure. However, haloperidol treatment group 
had higher baseline lactate levels than olanzapine group 
(P = 0.045, Table 1).
Comparison of antipsychotic treatment type and 
lactate levels
There was a significant main effect of both antipsychotic 
treatment types and treatment time on blood lactate lev-
els (Table 2), demonstrating that the increase in blood lac-
tate levels was achieved over time and more with halo-
peridol than with olanzapine. There was also a significant 
interaction  between  the  combination  of  antipsychotic 
treatment type and treatment time on blood lactate levels 
(F(1.43, 41.6) = 8.54, P < 0.01). For patients in the haloperidol 
group, the treatment resulted in the progressive increase 
in blood lactate levels from baseline to each time period; 
for patients in the olanzapine group, although the treat-
ment resulted in higher blood lactate levels from baseline 
TABle 1. Baseline characteristics among 60 patients taking first generation (haloperidol) or second generation (olanzapine) antipsy-
chotics
Patients receiving treatment with (mean ± standard deviation)
haloperidol (n = 30) olanzapine (n = 30) t P
Age   34.2 ± 9.8   31.1 ± 8.4 1.304 0.197
Blood lactate (mmol/L)   1 . 4  ± 0.4   1 . 2  ± 0.4 2.048 0.045
Weight (kg)   86.7 ± 11.5   85.3 ± 9.9 0.481 0.632
Glucose level (mg/dL)   5 . 3  ± 0.6   5 . 2  ± 0.6 0.625 0.535
Systolic blood pressure (mmHg) 131.5 ± 7.9 130.0 ± 7.2 0.769 0.445
Diastolic blood pressure (mmHg)   83.0 ± 6.6   82.5 ± 7.2 0.280 0.780
TABle 2. Interaction between antipsychotic treatment type (haloperidol and olanzapine) and time on blood lactate level
F Within group P value* Interaction P value* η2† α‡
Antipsychotic type 39.23 <0.001 0.575 1.000
Treatment time 12.69 <0.001 0.746 1.000
Antipsychotic type and treatment time   8.54 0.002 0.603 1.000
*P significance level.
†effect size.
‡observed statistical power.CLINICAL SCIENCES 44 Croat Med J. 2011; 52: 41-7
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to each time period, that difference was lower than that 
found in the haloperidol group (Table 3).
For  within-group  differences,  post-hoc  analysis  by  pair-
wise t test (Table 3) showed significant increase in mean 
blood lactate levels from baseline to each time point in the 
haloperidol group. In the olanzapine group, mean blood 
lactate levels increased from baseline to month 3 and 6, 
while no significant changes were found from baseline to 
month 1.
For between-group differences (Table 3), mean blood lac-
tate levels between patients in the haloperidol or olanzap-
ine group did not differ at baseline time point, but were 
significantly higher in patients receiving haloperidol than 
those receiving olanzapine at all other time points.
Frequency of extrapyramidal side effects
The frequencies of the four extrapyramidal side effects, as 
scored on the ESRS, are listed in Table 4. About 27% of pa-
tients receiving haloperidol and nearly 7% of patients re-
ceiving olanzapine reported moderate symptoms of par-
kinsonism. Of patients receiving haloperidol, 17% did not 
report any symptoms and more than one-third (37%) re-
ported symptoms of dystonia after 6 months. None of the 
patients receiving olanzapine reported any symptoms of 
dystonia or tardive dyskinesia.
TABle 3. Change in blood lactate levels in patients receiving haloperidol or olanzapine antipsychotics
Within-group change from baseline Between-group
difference haloperidol treatment (n = 30) olanzapine treatment (n = 30)
Month mean ± standard deviation P* mean ± standard deviation P* t P*
0 1.41 ± 0.44 1.20 ± 0.34 2.048   0.045
1 2.21 ± 1.05 <0.001 1.21 ± 0.31 0.743 4.989 <0.001
3 2.93 ± 2.01 <0.001 1.32 ± 0.35 0.015 4.303 <0.001
6 2.51 ± 0.78 <0.001 1.39 ± 0.37 0.001 7.01 <0.001
*Two-way repeated measures ANoVA with post-hoc comparisons.
TABle 4. extrapyramidal side effects in patients taking haloperidol or olanzapine antipsychotics
No. (%)of patients receiving treatment with
haloperidol (n = 30) olanzapine (n = 30)
Symptom baseline month 1 month 3 month 6 baseline month 1 month 3 month 6
Parkinsonism:
absent 30 (100) 16 (53) 14 (47) 15 (50) 28 (93) 26 (87) 23 (77) 21 (70)
mild   7 (23)   7 (23)   7 (23)   2 (7)   4 (13)   5 (17)   7 (23)
moderate   3 (10)   6 (20)   8 (27)   2 (7)   2 (7)
severe   4 (13)   3 (10)
Akathisia:
absent 29 (97) 26 (87) 24 (80) 25 (83) 30 (100) 30 (100) 27 (90) 27 (90)
mild   2 (7)   3 (10)   3 (10)   3 (10)   3 (10)
moderate   2 (7)   2 (7)   2 (7)
severe   1 (3)   1 (3)
Dystonia:
absent 30 (100) 21 (70) 18 (60) 19 (63) 30 (100) 30 (100) 30 (100) 30 (100)
mild   5 (17)   6 (20)   8 (27)
moderate   3 (10)   5 (17)   3 (10)
severe   1 (3)
Tardive dykinesia:
absent 30 (100) 27 (90) 26 (87) 26 (87) 30 (100) 30 (100) 30 (100) 30 (100)
mild   3 (10)   4 (13)   2 (7)
moderate   2 (7)
severe45 Glavina et al: Antipsychotics and blood lactate levels
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Correlation between blood lactate and extrapyramidal 
side effects
There was a strong and significant positive correlation be-
tween blood lactate and parkinsonism at month 1 (r = 0.64, 
P < 0.001) and moderate and significant positive correlation 
at month 6 (r = 0.44, P = 0.02) in patients receiving halo-
peridol (Table 5). Also, there was a strong and significant 
positive correlation between blood lactate and dystonia 
(r = 0.62, P < 0.001), and moderate and significant positive 
correlation between blood lactate and tardive dyskinesia 
at month 1 (r = 0.39, P = 0.03).
In patients receiving olanzapine, there was a correlation 
between blood lactate and parkinsonism at baseline and 3 
and 6 months (Table 6). There was no correlation between 
blood lactate and akathisia, dystonia, or tardive dyskinesia 
at any time points (Table 5, Table 6).
DISCUSSIoN
To our knowledge, the present study is the first that dem-
onstrated  that  haloperidol  or  olanzapine  antipsychot-
ic therapy changed blood lactate levels and caused ex-
trapyramidal side effects. We found significant increases in 
blood lactate levels and extrapyramidal side effects in both 
treatment groups, although the lactate levels were signifi-
cantly higher in the haloperidol than in olanzapine group. 
Moreover, the majority of patients in the haloperidol treat-
ment group reported extrapyramidal side effects. Our find-
ings are consistent with previous studies on greater inci-
dence of extrapyramidal side effects in patients treated 
with haloperidol, which increases the generalizability of 
our study. For example, several studies reported that halo-
peridol use was associated with increased extrapyramidal 
signs, particularly parkinsonism (12,36-39). Olanzapine use 
was associated with low incidence of extrapyramidal side 
effects in our study, which is also in accordance with other 
studies (32,39,40).
Previous studies have found hyperprolactinemia in criti-
cally ill patients, but not in psychiatric patients treated 
with  antipsychotics  (13,14,30,33). These  results  suggest 
that olanzapine and other second-generation antipsy-
chotic agents may have a lower tendency to increase 
blood lactate levels and cause extrapyramidal side 
TABle 5. Correlation between lactate and extrapyramidal side 
effects in patients receiving haloperidol treatment over time 
(n = 30)
Blood lactate
baseline month 1 month 3 month 6
Side effects r (P) r (P) r (P) r (P)
Parkinsonism:
baseline     0*
month 1     0.6 4 (<0.01)
month 3     0.31 (0.092)
month 6     0.4 4 (0.016)
Akathisia:
baseline -0.03(0.865)




baseline     0
month 1     0.62 (<0.01)
month 3     0.22 (0.251)
month 6     0.45 (0.012)
Tardive dyskinesia:
baseline     0
month 1     0.39 (0.03)2
month 3     0.30 (0.113)
month 6     0.31 (0.102)
*Symptom reported as absent in patients.
TABle 6. Correlation between lactate and extrapyramidal side 
effects in patients receiving olanzapine treatment over time 
(n = 30)
Blood lactate
baseline month 1 month 3 month 6




month 3     0.42 (0.019)














month 3     0
month 6 0
*Symptom reported as absent in patients.CLINICAL SCIENCES 46 Croat Med J. 2011; 52: 41-7
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effects over a 6-month period than first-generation agents, 
such as haloperidol. Although the mechanism of action of 
antipsychotic medications is not entirely explained, first-
generation antipsychotics have antidopaminergic activity, 
thus inducing prolactin secretion (12).
There are several limitations of this study. First, due to the 
non-randomized, observational study design, we had no 
control over the antipsychotic assignment, and therefore 
direct comparisons of treatment group outcomes may be 
misleading. Second, there was no true control group, be-
cause it would be impractical and unethical to deny treat-
ment to patients who need psychiatric medication. Fur-
ther prospective clinical studies are needed to determine 
the time course and magnitude of developing higher lac-
tate blood levels (>4.0 mmol/L) and extrapyramidal side 
effects.
This study showed that haloperidol therapy increases the 
lactate levels and the risk of parkinsonism, which affects 
the patients’ quality of life. Consequently, alternative antip-
sychotics can be prescribed with lower risk of increasing 
blood lactate levels (2,32,41).
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